Novo Nordisk A/S (NVO) has slashed prices for its blockbuster weight-loss drug Wegovy as competition in the obesity drug market heats up, with ...

Pfizer on Thursday named James List as the head of the drugmaker's Internal Medicine portfolio, where he will oversee the ...

A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and ...

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...

As a federal court in Texas hears a case pitting the FDA versus compounders who want to continue to manufacture cheaper ...

Novo Nordisk will start selling its obesity drug Wegovy directly to patients at a reduced price, following a similar move ...

Pfizer on Thursday named James List as the head of the drugmaker's Internal Medicine portfolio, where he will oversee the ...

Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, marking its entry into the obesity treatment market.

Pfizer reacts to Donald Trump’s tariff threats on big pharma, another regulatory meeting is canceled under RFK Jr., AbbVie ...

HHS Secretary Robert F. Kennedy Jr. is proposing to strip public participation from much of the business his agency conducts ...